

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

INSIDE INFORMATION ANNOUNCEMENT COMPLETION OF THE H SHARE FULL CIRCULATION

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

References are made to the inside information announcement dated June 30, 2022, the circular dated July 29, 2022, the announcement on the poll results of the EGM dated August 15, 2022, the announcement on the acceptance of application dated August 25, 2022, the announcement on the approval by the China Securities Regulatory Commission (the “**CSRC**”) dated November 10, 2022 and the announcement on the listing approval granted by the Stock Exchange dated December 5, 2022 (the “**Announcements and Circular**”) in relation to, among others, the particulars of the Company’s H Share Full Circulation Application and the approvals by the CSRC and the Stock Exchange of H Share Full Circulation Application of the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements and Circular.

The Company is pleased to announce that the conversion of 222,498,569 Domestic Shares of the Company into H Shares was completed on February 20, 2023, and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on February 21, 2023. The Participating Shareholders can only conduct share trading of the Converted H Shares subject to the completion of the onshore arrangement procedures as set out in the announcement of the Company dated December 5, 2022.

SHAREHOLDING STRUCTURE

The shareholding structure of the Company upon the completion of the Conversion and Listing is set out below:

Class of shares	As at the date of this announcement		Upon completion of the Conversion and Listing	
	Number of shares	Approximate percentage	Number of shares	Approximate percentage
Domestic Shares	377,322,880	78.13%	154,824,311	32.06%
Unlisted Foreign Shares	12,000,000	2.48%	12,000,000	2.48%
H Shares	93,640,120	19.39%	316,138,689	65.46%
Total	482,963,000	100%	482,963,000	100%

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, February 20, 2023

As at the date of this announcement, the Board comprises Dr. Liu Yong as the chairman of the Board and an executive director, Dr. Chen Jianping and Mr. Li Bu as executive directors, Dr. Hong Kunxue, Dr. Zhou Hongbin, Mr. Zhao Hui, Dr. Du Wei and Dr. Feng Tao as non-executive directors, and Mr. Liang Guodong, Dr. Xia Lijun, Professor Gao Feng and Professor Yuen Ming Fai as independent non-executive directors.